比利時(shí)艾爾貝姆Ion Beam Applications  www.iba-worldwide.com
IBA在癌癥診斷與治療領(lǐng)域中提供具有獨(dú)特精確度的解決方案。公司還提供消毒與電離方案以改善日常生活的衛(wèi)生與安全性。 對(duì)抗癌癥：腫瘤學(xué)連續(xù)體 | 
診斷 | 

IBA在粒子回旋加速器的設(shè)計(jì)以及放射性藥物示蹤劑的生產(chǎn)和分銷領(lǐng)域擁有獨(dú)特的專業(yè)技能。這些示蹤劑每天都在醫(yī)院中大量應(yīng)用，用來快速精確地探測癌、神經(jīng)和心臟疾病。
IBA還提供劑量測定產(chǎn)品，在大量醫(yī)院中用于質(zhì)量保證，在X射線診斷中用于患者劑量監(jiān)控。 
癌癥治療 | 

IBA開發(fā)了放射性治療方案和劑量測定設(shè)備，用來以最大的精確度來治療癌癥。
IBA是粒子治療領(lǐng)域內(nèi)的毫無爭議的領(lǐng)袖，被認(rèn)為是選擇性癌細(xì)胞破壞領(lǐng)域內(nèi)最精確和最有效的臨床放射性治療方法。 
消毒 & 電離 | 

IBA正在設(shè)計(jì)電子加速器和高能X射線，在大量行業(yè)中用于消毒醫(yī)療設(shè)備，對(duì)食品產(chǎn)品進(jìn)行高溫消毒，改善聚合物屬性。
200多臺(tái)IBA工業(yè)加速器被用于全球達(dá)幾十年之久。 

 
1947年：Louvain-la-neuve 天主教大學(xué)（UCL）的粒子回旋加速器研究中心生產(chǎn)了第一臺(tái)粒子回旋加速器。
1986年：基于UCL的粒子回旋加速器研究中心，IBA公司正式成立，公司的注冊(cè)辦公地點(diǎn)位于比利時(shí)的Louvain-la-Neuve。公司將目標(biāo)定位于利用在粒子加速器技術(shù)領(lǐng)域的專業(yè)技能來滿足在醫(yī)藥和工業(yè)領(lǐng)域中不斷增長的需求。
IBA最初從事醫(yī)學(xué)圖象處理，后來很快意識(shí)到了多元化的必要。因此，公司將注意力轉(zhuǎn)移到放射性治療，并開發(fā)了在治療各種癌癥時(shí)具有前所未有的精確度和效率的粒子回旋加速器。
1992年：IBA將業(yè)務(wù)拓展到消毒和電離等工業(yè)領(lǐng)域，向市場推出了Rhodotron。這是一種基于“法國核能委員會(huì)”提出的專利概念的粒子加速器。
1998年6月：IBA在Brussels證券市場上市并融資，這使得IBA能夠通過內(nèi)部增長和對(duì)其他公司的收購加速發(fā)展，所收購的公司的技術(shù)和服務(wù)加強(qiáng)或補(bǔ)充了IBA的核心競爭力。
IBA began its existence in 1986 as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), which produced its first cyclotron in 1947.
The objective was to exploit a unique expertise in particle accelerator technology to meet growing needs in the fields of medicine and industry.
While initially active in medical imaging, IBA quickly recognized the need to diversify. So, the company turned its attention to radiotherapy and developed cyclotrons able to treat numerous forms of cancer with a degree of precision and efficacy not possible before. Then, in 1992, IBA expanded activities into the industrial sector of Sterilization & Ionization by introducing the Rhodotron®, a new type of particle accelerator based on a patented concept of the French Atomic Energy Commission.

Funds raised on the Brussels stock market from an initial public offering in June 1998 enabled IBA to accelerate progress by internal growth and the acquisition of other companies, all offering technologies and services reinforcing or complementing IBA’s core competencies
IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for
healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is
also active in the field of industrial sterilization and ionization. Listed on the pan-European stock
exchange EURONEXT, IBA is included in the BelMid Index.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).